A W Tolcher1, K P Papadopoulos2, A Patnaik2, K Wilson3, S Thayer4, J Zanghi4, A T Gemo4, W M Kavanaugh4, H N Keer4, P M LoRusso3. 1. South Texas Accelerated Research Therapeutics (START), San Antonio atolcher@start.stoh.com. 2. South Texas Accelerated Research Therapeutics (START), San Antonio. 3. Wayne State University Hematology/Oncology, Karmanos Cancer Institute, Detroit. 4. Five Prime Therapeutics, Inc., South San Francisco, USA.
Abstract
BACKGROUND: Fibroblast growth factors (FGFs) play important roles in multiple cancers by supporting tumor growth and angiogenesis. FP-1039 (GSK3052230) is a FGF ligand trap consisting of the extracellular domain of FGF receptor 1 (FGFR1) fused with the Fc region of IgG1. FP-1039 binds and neutralizes multiple FGFs that normally bind FGFR1. The primary objective of this phase I study was to evaluate the safety and tolerability of FP-1039. PATIENTS AND METHODS: Eligible patients with metastatic or locally advanced solid tumors for which standard treatments were ineffective were treated with weekly doses of FP-1039 for 4 weeks, followed by 2 weeks observation. RESULTS: Thirty-nine subjects received a mean of 6 infusions of FP-1039 at doses ranging from 0.5 to 16 mg/kg weekly, with no maximally tolerated dose identified. Grade 3 or greater treatment emergent adverse events were uncommon. Four dose-limiting toxicities were reported at doses of 0.75 mg/kg (urticaria), 1 mg/kg (intestinal perforation and neutropenia), and 16 mg/kg (muscular weakness). Drug exposure was dose proportional, and the terminal elimination half-life was 2.6-3.9 days following a single dose. Target engagement as measured by low free plasma FGF2 levels was achieved. FGF pathway dysregulation was uncommon. No objective responses were observed. CONCLUSION: In nonselected cancer patients with advanced disease, treatment with FP-1039 was well tolerated and toxicities associated with small molecule drugs that inhibit FGFR tyrosine kinases, including hyperphosphatemia, were not observed. Further studies of FP-1039 in patients selected for FGF pathway dysregulation, who are most likely to benefit, are now underway.
BACKGROUND: Fibroblast growth factors (FGFs) play important roles in multiple cancers by supporting tumor growth and angiogenesis. FP-1039 (GSK3052230) is a FGF ligand trap consisting of the extracellular domain of FGF receptor 1 (FGFR1) fused with the Fc region of IgG1. FP-1039 binds and neutralizes multiple FGFs that normally bind FGFR1. The primary objective of this phase I study was to evaluate the safety and tolerability of FP-1039. PATIENTS AND METHODS: Eligible patients with metastatic or locally advanced solid tumors for which standard treatments were ineffective were treated with weekly doses of FP-1039 for 4 weeks, followed by 2 weeks observation. RESULTS: Thirty-nine subjects received a mean of 6 infusions of FP-1039 at doses ranging from 0.5 to 16 mg/kg weekly, with no maximally tolerated dose identified. Grade 3 or greater treatment emergent adverse events were uncommon. Four dose-limiting toxicities were reported at doses of 0.75 mg/kg (urticaria), 1 mg/kg (intestinal perforation and neutropenia), and 16 mg/kg (muscular weakness). Drug exposure was dose proportional, and the terminal elimination half-life was 2.6-3.9 days following a single dose. Target engagement as measured by low free plasma FGF2 levels was achieved. FGF pathway dysregulation was uncommon. No objective responses were observed. CONCLUSION: In nonselected cancerpatients with advanced disease, treatment with FP-1039 was well tolerated and toxicities associated with small molecule drugs that inhibit FGFR tyrosine kinases, including hyperphosphatemia, were not observed. Further studies of FP-1039 in patients selected for FGF pathway dysregulation, who are most likely to benefit, are now underway.
Authors: Emilie M J van Brummelen; Evgeny Levchenko; Manuel Dómine; Dean A Fennell; Hedy L Kindler; Santiago Viteri; Shirish Gadgeel; Pilar Garrido López; Vladimir Kostorov; Daniel Morgensztern; Sergey Orlov; Marjorie G Zauderer; Johan F Vansteenkiste; Katherine Baker-Neblett; James Vasquez; Xiaowei Wang; David I Bellovin; Jan H M Schellens; Li Yan; Ionel Mitrica; M Phillip DeYoung; José Trigo Journal: Invest New Drugs Date: 2019-05-07 Impact factor: 3.850
Authors: David P Perrault; Gene K Lee; Sun Young Park; Sunju Lee; Dongwon Choi; Eunson Jung; Young Jin Seong; Eun Kyung Park; Cynthia Sung; Roy Yu; Antoun Bouz; Austin Pourmoussa; Soo Jung Kim; Young-Kwon Hong; Alex K Wong Journal: Lymphat Res Biol Date: 2019-01-16 Impact factor: 2.589
Authors: Julia Chudzian; Anna Szlachcic; Malgorzata Zakrzewska; Miroslawa Czub; Marcin Pustula; Tad A Holak; Jacek Otlewski Journal: Int J Mol Sci Date: 2018-08-21 Impact factor: 5.923
Authors: Martyna Sochacka; Lukasz Opalinski; Jakub Szymczyk; Marta B Zimoch; Aleksandra Czyrek; Daniel Krowarsch; Jacek Otlewski; Malgorzata Zakrzewska Journal: Cell Commun Signal Date: 2020-05-01 Impact factor: 5.712